Selection from HEOR Bibliography

IMS logo
Search criteria
Country: Hungary
 
A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab) Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries
Authors: Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi
Affiliations: IQVIA, Courbevoie, France; Janssen EMEA, Medical Affairs, Italy; Janssen EMEA, Medical Affairs, UK
Publications: 
Presented at ISPE’s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2019), August 24–28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA.
Document Types: , Poster
Countries: , Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland
Abstract: https://www.coodoc.com/pages/p1822-Daratumumab-ICPE-2019
Condition Year Language Analysis type
, Hematology, Oncology 2019 English , Public Health, Survey research
 
 
Regional Differences in Insulin Therapy Regimens in 5 European Countries
Authors: Rathmann W, Czech M, Franek E, Kostev K
Affiliations: 
Publications: 
Int J Clin Pharmacol Ther. 2017 May;55(5):403-408.
Document Types: , Article
Countries: , France, Germany, Hungary, Poland, UK
Condition Year Language Analysis type
, Diabetes 2017 English
 
 
Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature.
Authors: Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1.
Affiliations: 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden.
Publications: 
Clinical Epidemiology
Document Types: , Article
Countries: , Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK
Abstract: http://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pmc/articles/PMC4887072/
Condition Year Language Analysis type
, Oncology 2016 English , Literature Review
 
 
Rationale and design of a multi-center survey to evaluate productivity losses and indirect costs after cardiovascular events in Europe.
Authors: Gerlier L1, Sidelnikov E2, Kutikova L2, Lamotte M1, Annemans L3
Affiliations: 1 QuintilesIMS, Zaventem, Belgium 2 Amgen (Europe) GmbH, Zug, Switzerland 3 University of Ghent, Ghent, Belgium
Publications: 
19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria
Document Types: , Abstract
Countries: , Belgium, Czech, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Switzerland, UK
Condition Year Language Analysis type
, Cardiovascular disease 2016 English
 
 
Survey on appropriateness of use of nimesulide in nine European countries
Authors: Franchi S1, Heiman F2, Visentin E2, Sacerdote P1.
Affiliations: 1Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. 2Cegedim Strategic Data Medical Research Srl, Milan, Italy.
Publications: 
Drug, Healthcare and Patient Safety 2015:7 51-55
Document Types: , Article
Countries: , Bulgaria, Czech, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia
Condition Year Language Analysis type
, Pain 2015 English , Survey research
 
 
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.
Authors: Palmer AJ, Valentine WJ, Ray JA, Roze S, Muszbek N.
Affiliations: 
Publications: 
Eur J Health Econ. 2007 Jun;8(2):161-8. Epub 2007 Jan 20
Document Types: , Manuscript in preparation
Countries: , Hungary
Abstract: http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007008181
Condition Year Language Analysis type
, Diabetes 2007 English , Cost effectiveness
 
 
Copyright 2023 IMS Health Incorporated. All rights reserved.